English

EMERGENT BIOSOLUTIONS INC.

EDGAR

EBS Current report (8-K) · filed 2026-10-16

Annual consolidated revenue for 2025: about USD 742.9M, using the latest reported figures. The previous period, 2024, was about USD 1.044B.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

234 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 234300000 USD Source

Operating margin

-53.39%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -125100000 USD Source
Revenue: 234300000 USD Source

Operating cash flow

56.1 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 22300000 USD Source
Operating Cash Flow: -33800000 USD Source

Free cash flow

54 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 22300000 USD Source
Operating Cash Flow: -33800000 USD Source
Capital Expenditure: 4500000 USD Source
Capital Expenditure: 2400000 USD Source

Cash and cash equivalents: 140 million USD 2026-06-30 Source
Exact value

139700000 USD
Long-term debt including current maturities: 590 million USD 2026-06-30 Source
Exact value

589700000 USD
Shares outstanding: 51.3 million shares 2026-06-30 Source
Exact value

51300000 shares

Reported share-count change

-4.47% · -2.4 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

53700000 shares · 2025-06-30· Source
51300000 shares · 2026-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-16.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2025-12-31
Operating income: 9 of 11 periods available· newest 2025-12-31
Net income: 9 of 11 periods available· newest 2025-12-31
Operating cash flow: 9 of 11 periods available· newest 2025-12-31
Capital expenditure: 9 of 11 periods available· newest 2025-12-31
Total assets: 8 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 8 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 8 of 11 periods available· newest 2025-12-31
Shares outstanding: 8 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-28.8%

Prior period

USD 1.04 billion

2024-01-01 – 2024-12-31
Current period

USD 742.9 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

742900000 − 1043600000 = -300700000 USD

1043600000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
742900000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · EMERGENT BIOSOLUTIONS INC. · 2025-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Year-over-year change in Revenue: -300700000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 742900000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#2597949 Filing: 000136764426000015 Input fundies:Revenue: 1043600000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#2598853 Filing: 000136764426000015
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 243.2 million

Prior period

−USD 190.6 million

2024-01-01 – 2024-12-31
Current period

USD 52.6 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

52600000 − -190600000 = 243200000 USD

-190600000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
52600000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · EMERGENT BIOSOLUTIONS INC. · 2025-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Year-over-year change in Net income: 243200000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 52600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#2184303 Filing: 000136764426000015 Input fundies:NetIncome: -190600000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#2185044 Filing: 000136764426000015
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+190.6%

Prior period

USD 58.7 million

2024-01-01 – 2024-12-31
Current period

USD 170.6 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

170600000 − 58700000 = 111900000 USD

58700000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
170600000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · EMERGENT BIOSOLUTIONS INC. · 2025-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Year-over-year change in Operating cash flow: 111900000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 170600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1437706 Filing: 000136764426000015 Input fundies:OperatingCashFlow: 58700000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1438324 Filing: 000136764426000015
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-39.7%

Prior period

USD 22.9 million

2024-01-01 – 2024-12-31
Current period

USD 13.8 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

13800000 − 22900000 = -9100000 USD

22900000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
13800000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · EMERGENT BIOSOLUTIONS INC. · 2025-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Year-over-year change in Capital expenditure: -9100000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 13800000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1440423 Filing: 000136764426000015 Input fundies:CapitalExpenditure: 22900000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1440984 Filing: 000136764426000015
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 742.9 million 100% of revenue
Cost of revenue USD 326.2 million 44% of revenue
Operating expenses USD 239.3 million 32% of revenue
Other operating costs Derived USD 77.3 million 10% of revenue
Operating income USD 100.1 million 13% of revenue
Tax, interest and other Derived USD 47.5 million 6.4% of revenue
Net income USD 52.6 million 7.1% of revenue

Cash

Operating cash flow USD 170.6 million 23% of revenue
Capital expenditure USD 13.8 million 1.9% of revenue
Free cash flow Derived USD 156.8 million 21% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 15%78%
2018 89%
2019 90%
2020 19%72%
2021 12%81%
2022 Operating loss: operating costs were 115% of revenue.
2023 Operating loss: operating costs were 169% of revenue.
2024 Operating loss: operating costs were 110% of revenue.
2025 87%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2017-01-01 – 2017-12-31	560900000	436600000 Derived	124300000	41700000 Derived	82600000	153300000 Derived	Source 2017-01-01 – 2017-12-31: 560900000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: 124300000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: 82600000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: 208100000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 54800000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	782400000	692600000 Derived	89800000	27100000 Derived	62700000	-30300000 Derived	Source 2018-01-01 – 2018-12-31: 782400000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: 89800000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: 62700000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 41800000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 72100000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	1106000000	991900000 Derived	114100000	59600000 Derived	54500000	101100000 Derived	Source 2019-01-01 – 2019-12-31: 1106000000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: 114100000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: 54500000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 188000000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 86900000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	1577300000	1138800000 Derived	438500000	132700000 Derived	305800000	395000000 Derived	Source 2020-01-01 – 2020-12-31: 1577300000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: 438500000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 305800000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 536900000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 141900000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	1773600000	1432200000 Derived	341400000	121900000 Derived	219500000	96100000 Derived	Source 2021-01-01 – 2021-12-31: 1773600000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 341400000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 219500000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 320200000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 224100000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	1117500000	1287500000 Derived	-170000000	41600000 Derived	-211600000	-149900000 Derived	Source 2022-01-01 – 2022-12-31: 1117500000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -170000000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -211600000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -34100000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 115800000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	1049300000	1775700000 Derived	-726400000	34100000 Derived	-760500000	-257900000 Derived	Source 2023-01-01 – 2023-12-31: 1049300000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -726400000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -760500000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -206300000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 51600000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	1043600000	1152300000 Derived	-108700000	81900000 Derived	-190600000	35800000 Derived	Source 2024-01-01 – 2024-12-31: 1043600000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -108700000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -190600000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: 58700000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 22900000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	742900000	642800000 Derived	100100000	47500000 Derived	52600000	156800000 Derived	Source 2025-01-01 – 2025-12-31: 742900000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: 100100000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: 52600000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: 170600000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 13800000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 742.9M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Revenue	560900000	Revenue: 560900000 Open source
20182018-12-31	Revenue	782400000	Revenue: 782400000 Open source
20192019-12-31	Revenue	1106000000	Revenue: 1106000000 Open source
20202020-12-31	Revenue	1577300000	Revenue: 1577300000 Open source
20212021-12-31	Revenue	1773600000	Revenue: 1773600000 Open source
20222022-12-31	Revenue	1117500000	Revenue: 1117500000 Open source
20232023-12-31	Revenue	1049300000	Revenue: 1049300000 Open source
20242024-12-31	Revenue	1043600000	Revenue: 1043600000 Open source
20252025-12-31	Revenue	742900000	Revenue: 742900000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-28.8% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Year over year	No prior comparable period	Revenue: 560900000 Open source
20182018-12-31	Year over year	39.5%	Revenue: 782400000 Open source Revenue: 560900000 Open source
20192019-12-31	Year over year	41.4%	Revenue: 1106000000 Open source Revenue: 782400000 Open source
20202020-12-31	Year over year	42.6%	Revenue: 1577300000 Open source Revenue: 1106000000 Open source
20212021-12-31	Year over year	12.4%	Revenue: 1773600000 Open source Revenue: 1577300000 Open source
20222022-12-31	Year over year	-37%	Revenue: 1117500000 Open source Revenue: 1773600000 Open source
20232023-12-31	Year over year	-6.1%	Revenue: 1049300000 Open source Revenue: 1117500000 Open source
20242024-12-31	Year over year	-0.5%	Revenue: 1043600000 Open source Revenue: 1049300000 Open source
20252025-12-31	Year over year	-28.8%	Revenue: 742900000 Open source Revenue: 1043600000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 13.5% 2025

Net margin 7.1% 2025

Free cash flow margin 21.1% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Operating margin	22.2%	Operating Income: 124300000 Open source Revenue: 560900000 Open source
20182018-12-31	Operating margin	11.5%	Operating Income: 89800000 Open source Revenue: 782400000 Open source
20192019-12-31	Operating margin	10.3%	Operating Income: 114100000 Open source Revenue: 1106000000 Open source
20202020-12-31	Operating margin	27.8%	Operating Income: 438500000 Open source Revenue: 1577300000 Open source
20212021-12-31	Operating margin	19.2%	Operating Income: 341400000 Open source Revenue: 1773600000 Open source
20222022-12-31	Operating margin	-15.2%	Operating Income: -170000000 Open source Revenue: 1117500000 Open source
20232023-12-31	Operating margin	-69.2%	Operating Income: -726400000 Open source Revenue: 1049300000 Open source
20242024-12-31	Operating margin	-10.4%	Operating Income: -108700000 Open source Revenue: 1043600000 Open source
20252025-12-31	Operating margin	13.5%	Operating Income: 100100000 Open source Revenue: 742900000 Open source
20172017-12-31	Net margin	14.7%	Net Income: 82600000 Open source Revenue: 560900000 Open source
20182018-12-31	Net margin	8%	Net Income: 62700000 Open source Revenue: 782400000 Open source
20192019-12-31	Net margin	4.9%	Net Income: 54500000 Open source Revenue: 1106000000 Open source
20202020-12-31	Net margin	19.4%	Net Income: 305800000 Open source Revenue: 1577300000 Open source
20212021-12-31	Net margin	12.4%	Net Income: 219500000 Open source Revenue: 1773600000 Open source
20222022-12-31	Net margin	-18.9%	Net Income: -211600000 Open source Revenue: 1117500000 Open source
20232023-12-31	Net margin	-72.5%	Net Income: -760500000 Open source Revenue: 1049300000 Open source
20242024-12-31	Net margin	-18.3%	Net Income: -190600000 Open source Revenue: 1043600000 Open source
20252025-12-31	Net margin	7.1%	Net Income: 52600000 Open source Revenue: 742900000 Open source
20172017-12-31	Free cash flow margin	27.3%	Revenue: 560900000 Open source Operating Cash Flow: 208100000 Open source Capital Expenditure: 54800000 Open source
20182018-12-31	Free cash flow margin	-3.9%	Revenue: 782400000 Open source Operating Cash Flow: 41800000 Open source Capital Expenditure: 72100000 Open source
20192019-12-31	Free cash flow margin	9.1%	Revenue: 1106000000 Open source Operating Cash Flow: 188000000 Open source Capital Expenditure: 86900000 Open source
20202020-12-31	Free cash flow margin	25%	Revenue: 1577300000 Open source Operating Cash Flow: 536900000 Open source Capital Expenditure: 141900000 Open source
20212021-12-31	Free cash flow margin	5.4%	Revenue: 1773600000 Open source Operating Cash Flow: 320200000 Open source Capital Expenditure: 224100000 Open source
20222022-12-31	Free cash flow margin	-13.4%	Revenue: 1117500000 Open source Operating Cash Flow: -34100000 Open source Capital Expenditure: 115800000 Open source
20232023-12-31	Free cash flow margin	-24.6%	Revenue: 1049300000 Open source Operating Cash Flow: -206300000 Open source Capital Expenditure: 51600000 Open source
20242024-12-31	Free cash flow margin	3.4%	Revenue: 1043600000 Open source Operating Cash Flow: 58700000 Open source Capital Expenditure: 22900000 Open source
20252025-12-31	Free cash flow margin	21.1%	Revenue: 742900000 Open source Operating Cash Flow: 170600000 Open source Capital Expenditure: 13800000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 170.6M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Operating cash flow	208100000	Operating Cash Flow: 208100000 Open source
20182018-12-31	Operating cash flow	41800000	Operating Cash Flow: 41800000 Open source
20192019-12-31	Operating cash flow	188000000	Operating Cash Flow: 188000000 Open source
20202020-12-31	Operating cash flow	536900000	Operating Cash Flow: 536900000 Open source
20212021-12-31	Operating cash flow	320200000	Operating Cash Flow: 320200000 Open source
20222022-12-31	Operating cash flow	-34100000	Operating Cash Flow: -34100000 Open source
20232023-12-31	Operating cash flow	-206300000	Operating Cash Flow: -206300000 Open source
20242024-12-31	Operating cash flow	58700000	Operating Cash Flow: 58700000 Open source
20252025-12-31	Operating cash flow	170600000	Operating Cash Flow: 170600000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 156.8M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Free cash flow	153300000	Operating Cash Flow: 208100000 Open source Capital Expenditure: 54800000 Open source
20182018-12-31	Free cash flow	-30300000	Operating Cash Flow: 41800000 Open source Capital Expenditure: 72100000 Open source
20192019-12-31	Free cash flow	101100000	Operating Cash Flow: 188000000 Open source Capital Expenditure: 86900000 Open source
20202020-12-31	Free cash flow	395000000	Operating Cash Flow: 536900000 Open source Capital Expenditure: 141900000 Open source
20212021-12-31	Free cash flow	96100000	Operating Cash Flow: 320200000 Open source Capital Expenditure: 224100000 Open source
20222022-12-31	Free cash flow	-149900000	Operating Cash Flow: -34100000 Open source Capital Expenditure: 115800000 Open source
20232023-12-31	Free cash flow	-257900000	Operating Cash Flow: -206300000 Open source Capital Expenditure: 51600000 Open source
20242024-12-31	Free cash flow	35800000	Operating Cash Flow: 58700000 Open source Capital Expenditure: 22900000 Open source
20252025-12-31	Free cash flow	156800000	Operating Cash Flow: 170600000 Open source Capital Expenditure: 13800000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

60.4% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2017-12-31	Liabilities / assets	Not reported	No source recorded
20182018-12-31	Liabilities / assets	54.7%	Total Liabilities: 1218500000 Open source Total Assets: 2229400000 Open source
20192019-12-31	Liabilities / assets	53.2%	Total Liabilities: 1238800000 Open source Total Assets: 2327300000 Open source
20202020-12-31	Liabilities / assets	49.8%	Total Liabilities: 1436200000 Open source Total Assets: 2883200000 Open source
20212021-12-31	Liabilities / assets	45.5%	Total Liabilities: 1346200000 Open source Total Assets: 2957700000 Open source
20222022-12-31	Liabilities / assets	56.2%	Total Liabilities: 1778600000 Open source Total Assets: 3166300000 Open source
20232023-12-31	Liabilities / assets	64.4%	Total Liabilities: 1173900000 Open source Total Assets: 1823200000 Open source
20242024-12-31	Liabilities / assets	65.3%	Total Liabilities: 906900000 Open source Total Assets: 1389700000 Open source
20252025-12-31	Liabilities / assets	60.4%	Total Liabilities: 796000000 Open source Total Assets: 1318600000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.01× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2017-12-31	Current assets / current liabilities	Not reported	No source recorded
20182018-12-31	Current assets / current liabilities	3.1×	Current Assets: 620800000 Open source Current Liabilities: 200400000 Open source
20192019-12-31	Current assets / current liabilities	3.17×	Current Assets: 686200000 Open source Current Liabilities: 216300000 Open source
20202020-12-31	Current assets / current liabilities	3.11×	Current Assets: 1195900000 Open source Current Liabilities: 384500000 Open source
20212021-12-31	Current assets / current liabilities	3.4×	Current Assets: 1269900000 Open source Current Liabilities: 374000000 Open source
20222022-12-31	Current assets / current liabilities	0.98×	Current Assets: 1210400000 Open source Current Liabilities: 1228900000 Open source
20232023-12-31	Current assets / current liabilities	1.04×	Current Assets: 679500000 Open source Current Liabilities: 651300000 Open source
20242024-12-31	Current assets / current liabilities	3.69×	Current Assets: 598700000 Open source Current Liabilities: 162400000 Open source
20252025-12-31	Current assets / current liabilities	5.01×	Current Assets: 662500000 Open source Current Liabilities: 132200000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	USD 82.6 million Exact value Exact value: 82600000 USD 2017-01-01 – 2017-12-31: 82600000 USD Inspect Net Income Open source Share or cite Citation for Net Income · EMERGENT BIOSOLUTIONS INC. · 2017-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Net Income: 82600000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: 82600000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764420000010/ebs-2019123110k.htm#2855318 Filing: 000136764420000010 The citation records this snapshot. The page link may show a newer release later.	USD 208.1 million Exact value Exact value: 208100000 USD 2017-01-01 – 2017-12-31: 208100000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · EMERGENT BIOSOLUTIONS INC. · 2017-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Operating Cash Flow: 208100000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 208100000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764420000010/ebs-2019123110k.htm#1512670 Filing: 000136764420000010 The citation records this snapshot. The page link may show a newer release later.	USD 54.8 million Exact value Exact value: 54800000 USD 2017-01-01 – 2017-12-31: 54800000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · EMERGENT BIOSOLUTIONS INC. · 2017-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Capital Expenditure: 54800000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 54800000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764420000010/ebs-2019123110k.htm#1517098 Filing: 000136764420000010 The citation records this snapshot. The page link may show a newer release later.	USD 153.3 million Calculation and evidence 208100000 − 54800000 USD Exact free cash flow: 153300000 USD 2017-01-01 – 2017-12-31: 208100000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 54800000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · EMERGENT BIOSOLUTIONS INC. · 2017-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Free cash flow: 153300000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 208100000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764420000010/ebs-2019123110k.htm#1512670 Filing: 000136764420000010 Input fundies:CapitalExpenditure: 54800000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764420000010/ebs-2019123110k.htm#1517098 Filing: 000136764420000010 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	USD 62.7 million Exact value Exact value: 62700000 USD 2018-01-01 – 2018-12-31: 62700000 USD Inspect Net Income Open source Share or cite Citation for Net Income · EMERGENT BIOSOLUTIONS INC. · 2018-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Net Income: 62700000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: 62700000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/ebs-20201231.htm#2487842 Filing: 000136764421000033 The citation records this snapshot. The page link may show a newer release later.	USD 41.8 million Exact value Exact value: 41800000 USD 2018-01-01 – 2018-12-31: 41800000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · EMERGENT BIOSOLUTIONS INC. · 2018-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Operating Cash Flow: 41800000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 41800000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/ebs-20201231.htm#1224377 Filing: 000136764421000033 The citation records this snapshot. The page link may show a newer release later.	USD 72.1 million Exact value Exact value: 72100000 USD 2018-01-01 – 2018-12-31: 72100000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · EMERGENT BIOSOLUTIONS INC. · 2018-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Capital Expenditure: 72100000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 72100000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/ebs-20201231.htm#1227937 Filing: 000136764421000033 The citation records this snapshot. The page link may show a newer release later.	−USD 30.3 million Calculation and evidence 41800000 − 72100000 USD Exact free cash flow: -30300000 USD 2018-01-01 – 2018-12-31: 41800000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 72100000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · EMERGENT BIOSOLUTIONS INC. · 2018-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Free cash flow: -30300000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 41800000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/ebs-20201231.htm#1224377 Filing: 000136764421000033 Input fundies:CapitalExpenditure: 72100000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764421000033/ebs-20201231.htm#1227937 Filing: 000136764421000033 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	USD 54.5 million Exact value Exact value: 54500000 USD 2019-01-01 – 2019-12-31: 54500000 USD Inspect Net Income Open source Share or cite Citation for Net Income · EMERGENT BIOSOLUTIONS INC. · 2019-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Net Income: 54500000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: 54500000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/ebs-20211231.htm#2557065 Filing: 000136764422000024 The citation records this snapshot. The page link may show a newer release later.	USD 188 million Exact value Exact value: 188000000 USD 2019-01-01 – 2019-12-31: 188000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · EMERGENT BIOSOLUTIONS INC. · 2019-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Operating Cash Flow: 188000000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 188000000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/ebs-20211231.htm#1288729 Filing: 000136764422000024 The citation records this snapshot. The page link may show a newer release later.	USD 86.9 million Exact value Exact value: 86900000 USD 2019-01-01 – 2019-12-31: 86900000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · EMERGENT BIOSOLUTIONS INC. · 2019-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Capital Expenditure: 86900000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 86900000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/ebs-20211231.htm#1292270 Filing: 000136764422000024 The citation records this snapshot. The page link may show a newer release later.	USD 101.1 million Calculation and evidence 188000000 − 86900000 USD Exact free cash flow: 101100000 USD 2019-01-01 – 2019-12-31: 188000000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 86900000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · EMERGENT BIOSOLUTIONS INC. · 2019-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Free cash flow: 101100000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 188000000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/ebs-20211231.htm#1288729 Filing: 000136764422000024 Input fundies:CapitalExpenditure: 86900000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000024/ebs-20211231.htm#1292270 Filing: 000136764422000024 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 305.8 million Exact value Exact value: 305800000 USD 2020-01-01 – 2020-12-31: 305800000 USD Inspect Net Income Open source Share or cite Citation for Net Income · EMERGENT BIOSOLUTIONS INC. · 2020-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Net Income: 305800000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 305800000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000207/ebs-20221231.htm#2339540 Filing: 000136764423000207 The citation records this snapshot. The page link may show a newer release later.	USD 536.9 million Exact value Exact value: 536900000 USD 2020-01-01 – 2020-12-31: 536900000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · EMERGENT BIOSOLUTIONS INC. · 2020-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Operating Cash Flow: 536900000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 536900000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000207/ebs-20221231.htm#1810283 Filing: 000136764423000207 The citation records this snapshot. The page link may show a newer release later.	USD 141.9 million Exact value Exact value: 141900000 USD 2020-01-01 – 2020-12-31: 141900000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · EMERGENT BIOSOLUTIONS INC. · 2020-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Capital Expenditure: 141900000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 141900000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000207/ebs-20221231.htm#1812685 Filing: 000136764423000207 The citation records this snapshot. The page link may show a newer release later.	USD 395 million Calculation and evidence 536900000 − 141900000 USD Exact free cash flow: 395000000 USD 2020-01-01 – 2020-12-31: 536900000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 141900000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · EMERGENT BIOSOLUTIONS INC. · 2020-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Free cash flow: 395000000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 536900000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000207/ebs-20221231.htm#1810283 Filing: 000136764423000207 Input fundies:CapitalExpenditure: 141900000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000207/ebs-20221231.htm#1812685 Filing: 000136764423000207 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 219.5 million Exact value Exact value: 219500000 USD 2021-01-01 – 2021-12-31: 219500000 USD Inspect Net Income Open source Share or cite Citation for Net Income · EMERGENT BIOSOLUTIONS INC. · 2021-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Net Income: 219500000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 219500000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000033/ebs-20231231.htm#2374295 Filing: 000136764424000033 The citation records this snapshot. The page link may show a newer release later.	USD 320.2 million Exact value Exact value: 320200000 USD 2021-01-01 – 2021-12-31: 320200000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · EMERGENT BIOSOLUTIONS INC. · 2021-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Operating Cash Flow: 320200000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 320200000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000033/ebs-20231231.htm#1660683 Filing: 000136764424000033 The citation records this snapshot. The page link may show a newer release later.	USD 224.1 million Exact value Exact value: 224100000 USD 2021-01-01 – 2021-12-31: 224100000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · EMERGENT BIOSOLUTIONS INC. · 2021-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Capital Expenditure: 224100000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 224100000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000033/ebs-20231231.htm#1663298 Filing: 000136764424000033 The citation records this snapshot. The page link may show a newer release later.	USD 96.1 million Calculation and evidence 320200000 − 224100000 USD Exact free cash flow: 96100000 USD 2021-01-01 – 2021-12-31: 320200000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 224100000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · EMERGENT BIOSOLUTIONS INC. · 2021-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Free cash flow: 96100000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 320200000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000033/ebs-20231231.htm#1660683 Filing: 000136764424000033 Input fundies:CapitalExpenditure: 224100000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000033/ebs-20231231.htm#1663298 Filing: 000136764424000033 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 211.6 million Exact value Exact value: -211600000 USD 2022-01-01 – 2022-12-31: -211600000 USD Inspect Net Income Open source Share or cite Citation for Net Income · EMERGENT BIOSOLUTIONS INC. · 2022-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Net Income: -211600000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -211600000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000021/ebs-20241231.htm#2486594 Filing: 000136764425000021 The citation records this snapshot. The page link may show a newer release later.	−USD 34.1 million Exact value Exact value: -34100000 USD 2022-01-01 – 2022-12-31: -34100000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · EMERGENT BIOSOLUTIONS INC. · 2022-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Operating Cash Flow: -34100000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -34100000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000021/ebs-20241231.htm#1735586 Filing: 000136764425000021 The citation records this snapshot. The page link may show a newer release later.	USD 115.8 million Exact value Exact value: 115800000 USD 2022-01-01 – 2022-12-31: 115800000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · EMERGENT BIOSOLUTIONS INC. · 2022-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Capital Expenditure: 115800000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 115800000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000021/ebs-20241231.htm#1738213 Filing: 000136764425000021 The citation records this snapshot. The page link may show a newer release later.	−USD 149.9 million Calculation and evidence -34100000 − 115800000 USD Exact free cash flow: -149900000 USD 2022-01-01 – 2022-12-31: -34100000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 115800000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · EMERGENT BIOSOLUTIONS INC. · 2022-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Free cash flow: -149900000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -34100000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000021/ebs-20241231.htm#1735586 Filing: 000136764425000021 Input fundies:CapitalExpenditure: 115800000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000021/ebs-20241231.htm#1738213 Filing: 000136764425000021 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 760.5 million Exact value Exact value: -760500000 USD 2023-01-01 – 2023-12-31: -760500000 USD Inspect Net Income Open source Share or cite Citation for Net Income · EMERGENT BIOSOLUTIONS INC. · 2023-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Net Income: -760500000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -760500000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#2185791 Filing: 000136764426000015 The citation records this snapshot. The page link may show a newer release later.	−USD 206.3 million Exact value Exact value: -206300000 USD 2023-01-01 – 2023-12-31: -206300000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · EMERGENT BIOSOLUTIONS INC. · 2023-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Operating Cash Flow: -206300000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -206300000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1438943 Filing: 000136764426000015 The citation records this snapshot. The page link may show a newer release later.	USD 51.6 million Exact value Exact value: 51600000 USD 2023-01-01 – 2023-12-31: 51600000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · EMERGENT BIOSOLUTIONS INC. · 2023-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Capital Expenditure: 51600000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 51600000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1441546 Filing: 000136764426000015 The citation records this snapshot. The page link may show a newer release later.	−USD 257.9 million Calculation and evidence -206300000 − 51600000 USD Exact free cash flow: -257900000 USD 2023-01-01 – 2023-12-31: -206300000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 51600000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · EMERGENT BIOSOLUTIONS INC. · 2023-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Free cash flow: -257900000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -206300000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1438943 Filing: 000136764426000015 Input fundies:CapitalExpenditure: 51600000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1441546 Filing: 000136764426000015 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 190.6 million Exact value Exact value: -190600000 USD 2024-01-01 – 2024-12-31: -190600000 USD Inspect Net Income Open source Share or cite Citation for Net Income · EMERGENT BIOSOLUTIONS INC. · 2024-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Net Income: -190600000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -190600000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#2185044 Filing: 000136764426000015 The citation records this snapshot. The page link may show a newer release later.	USD 58.7 million Exact value Exact value: 58700000 USD 2024-01-01 – 2024-12-31: 58700000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · EMERGENT BIOSOLUTIONS INC. · 2024-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Operating Cash Flow: 58700000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 58700000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1438324 Filing: 000136764426000015 The citation records this snapshot. The page link may show a newer release later.	USD 22.9 million Exact value Exact value: 22900000 USD 2024-01-01 – 2024-12-31: 22900000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · EMERGENT BIOSOLUTIONS INC. · 2024-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Capital Expenditure: 22900000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 22900000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1440984 Filing: 000136764426000015 The citation records this snapshot. The page link may show a newer release later.	USD 35.8 million Calculation and evidence 58700000 − 22900000 USD Exact free cash flow: 35800000 USD 2024-01-01 – 2024-12-31: 58700000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 22900000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · EMERGENT BIOSOLUTIONS INC. · 2024-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Free cash flow: 35800000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 58700000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1438324 Filing: 000136764426000015 Input fundies:CapitalExpenditure: 22900000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1440984 Filing: 000136764426000015 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	USD 52.6 million Exact value Exact value: 52600000 USD 2025-01-01 – 2025-12-31: 52600000 USD Inspect Net Income Open source Share or cite Citation for Net Income · EMERGENT BIOSOLUTIONS INC. · 2025-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Net Income: 52600000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: 52600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#2184303 Filing: 000136764426000015 The citation records this snapshot. The page link may show a newer release later.	USD 170.6 million Exact value Exact value: 170600000 USD 2025-01-01 – 2025-12-31: 170600000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · EMERGENT BIOSOLUTIONS INC. · 2025-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Operating Cash Flow: 170600000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 170600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1437706 Filing: 000136764426000015 The citation records this snapshot. The page link may show a newer release later.	USD 13.8 million Exact value Exact value: 13800000 USD 2025-01-01 – 2025-12-31: 13800000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · EMERGENT BIOSOLUTIONS INC. · 2025-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Capital Expenditure: 13800000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 13800000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1440423 Filing: 000136764426000015 The citation records this snapshot. The page link may show a newer release later.	USD 156.8 million Calculation and evidence 170600000 − 13800000 USD Exact free cash flow: 156800000 USD 2025-01-01 – 2025-12-31: 170600000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 13800000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · EMERGENT BIOSOLUTIONS INC. · 2025-12-31 EMERGENT BIOSOLUTIONS INC. (edgar:1367644) Free cash flow: 156800000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 170600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1437706 Filing: 000136764426000015 Input fundies:CapitalExpenditure: 13800000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm#1440423 Filing: 000136764426000015 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

140 filings · 7,664 latest values · 7,664 originally reported values

Dataset published 2026-11-03. Source filing dates and reporting periods are shown separately.

Identifiers: 0001367644, 1367644, EBS, edgar:1367644

Also known as EMERGENT BIOSOLUTIONS INC., Emergent BioSolutions Inc.

EMERGENT BIOSOLUTIONS INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation